États-Unis · Plateformes & données · Yahoo Finance

KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial

Publié par Yahoo Finance · États-Unis il y a 9 h

PITTSBURGH, November 06, 2026--(BUSINESS WIRE)--KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy…

Lire l'article complet sur Yahoo Finance Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)

KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial

À lire aussi

Franklin (BEN) Q4 2026 Earnings Call Transcript

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Haiti PM says gang leader Mathias Saintil dead

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Tech Bounces, but the S&P 500 Still Has Its Worst Week Since April 2025

KaliVir Immunotherapeutics Reports 71% Objective Response Rate in Patients with Advanced, Cutaneous Malignancies in Phase 1/1b STEALTH-001 Trial

Partager

À lire aussi

Franklin (BEN) Q4 2026 Earnings Call Transcript

Gogo reiterates $870M-$895M 2026 revenue guidance while outlining Galileo speeds to over 1 gigabit by 2032

Haiti PM says gang leader Mathias Saintil dead

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

Nasdaq drops into correction territory — here’s what typically happens next

Tech Bounces, but the S&P 500 Still Has Its Worst Week Since April 2025